Fludarabine monophosphate

DRUG10 trials

Sponsors

Masonic Cancer Center, University of Minnesota, Nationwide Children's Hospital, M.D. Anderson Cancer Center, Ivan S Moiseev, St. Petersburg State Pavlov Medical University

Conditions

Acute Lymphocytic LeukemiaAcute Lymphoid LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Myeloid LeukemiaDiamond-Blackfan AnemiaHodgkins LymphomaImmune System Diseases

Phase 1

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

CompletedNCT02799147

St. Petersburg State Pavlov Medical UniversityAcute Myeloid Leukemia, Leukemia, Acute Lymphoblastic, Mixed-Lineage Acute Leukemias

Start: 2016-06-30End: 2020-11-30Updated: 2020-11-23

PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis

CompletedNCT02806375

St. Petersburg State Pavlov Medical UniversityMyeloproliferative Disorders, Primary Myelofibrosis

Start: 2016-01-31End: 2019-04-30Updated: 2019-04-04

Phase 2

Stem Cell Transplant for Bone Marrow Failure Syndromes

CompletedNCT00176878

Masonic Cancer Center, University of MinnesotaDiamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome

Start: 2000-06-30End: 2009-03-31Updated: 2017-12-28

Allogeneic Transplantation For Severe Osteopetrosis

CompletedNCT00775931

Masonic Cancer Center, University of MinnesotaSevere Osteopetrosis

Start: 2008-08-31End: 2013-06-30Updated: 2019-07-31

A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

TerminatedNCT01279616

Nationwide Children's HospitalSickle Cell Disease

Start: 2010-09-30End: 2015-01-31Updated: 2019-04-03

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

CompletedNCT01572662

M.D. Anderson Cancer CenterAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia +7

Start: 2012-04-11End: 2022-08-11Updated: 2023-06-29

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

CompletedNCT02294552

Ivan S MoiseevAcute Lymphoid Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia +3

Start: 2014-10-31End: 2017-11-30Updated: 2018-01-16

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

TerminatedNCT02627573

St. Petersburg State Pavlov Medical UniversityLeukemia, Chronic Myeloid, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Myelodysplastic Syndromes

Start: 2015-07-31End: 2019-04-03Updated: 2019-04-05

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

CompletedNCT02757885

Emory UniversitySickle Cell Disease

Start: 2019-07-10End: 2021-12-14Updated: 2023-10-12

HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen

National Guard Health AffairsSickle Cell Disease

Start: 2016-05-31End: 2019-12-31Target: 15Updated: 2016-05-19

Related Papers

Graft-versus-Host Disease Prophylaxis with Post-Transplantation Bendamustine in Patients with Refractory Acute Leukemia: A Dose-Ranging Study.

2021-05-075 citations

Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial

Blood2020-11-04

Randomized study between thymoglobulin and posttransplant cyclophosphamide in patients with chronic myeloid neoplasms undergoing unrelated allogeneic stem cell transplantation

Cellular Therapy and Transplantation2020-04-284 citations

A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis

Acta Haematologica2020-04-2337 citations

Hematopoietic Stem Cell Transplantation in Children with Sickle Cell Disease: Myeloablative Versus Reduced Intensity Conditioning

Biology of Blood and Marrow Transplantation2020-01-23

Graft-Versus Host Disease Prophylaxis with Postransplantation Bendamustine in Refractory Leaukemia Patients

Blood2019-11-131 citations

High prevalence of CD3, NK, and NKT cells in the graft predicts adverse outcome after matched-related and unrelated transplantations with post transplantation cyclophosphamide.

2019-09-207 citations

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

BMC Cancer2018-11-1954 citations

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.

2018-11-0120 citations

Risk‐adapted <scp>GVHD</scp> prophylaxis with post‐transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations

European Journal Of Haematology2018-01-2325 citations

Graft-Versus-Host Disease Prophylaxis with Posttransplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis

Blood2017-12-072 citations

Better survival with fludarabine and timed sequential busulfan regimen in older patients with AML/MDS.

Journal of Clinical Oncology2017-05-20

Prevention of Acute Graft-Versus-Host Reaction after Allogeneic Unrelated Hematopoietic Stem Cell Transplantation: Comparison of Effectiveness of Treatment Regimens Based on Anti-Thymocyte Globulin and Cyclophosphamide

Clinical oncohematology2016-10-011 citations

Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil

Biology of Blood and Marrow Transplantation2016-03-09114 citations